JW (Cayman) Therapeutics Co Ltd
HKEX:2126
JW (Cayman) Therapeutics Co Ltd
Cash from Financing Activities
JW (Cayman) Therapeutics Co Ltd
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
JW (Cayman) Therapeutics Co Ltd
HKEX:2126
|
Cash from Financing Activities
¥112.4m
|
CAGR 3-Years
-66%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Cash from Financing Activities
-¥448.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Cash from Financing Activities
¥2.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cash from Financing Activities
-¥893.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-98%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cash from Financing Activities
-¥2.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-39%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cash from Financing Activities
-¥374.2m
|
CAGR 3-Years
-104%
|
CAGR 5-Years
-98%
|
CAGR 10-Years
N/A
|
See Also
What is JW (Cayman) Therapeutics Co Ltd's Cash from Financing Activities?
Cash from Financing Activities
112.4m
CNY
Based on the financial report for Dec 31, 2023, JW (Cayman) Therapeutics Co Ltd's Cash from Financing Activities amounts to 112.4m CNY.
What is JW (Cayman) Therapeutics Co Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-15%
Over the last year, the Cash from Financing Activities growth was 0%. The average annual Cash from Financing Activities growth rates for JW (Cayman) Therapeutics Co Ltd have been -66% over the past three years , -15% over the past five years .